REDUCED INTENSITY (FB2) VS REDUCED TOXICITY MYELOABLATIVE (FB3‐4) FLUDARABINE/BUSULFAN‐BASED CONDITIONING REGIMENS FOR NON‐HODGKIN LYMPHOMA (NHL) ALLOGRAFTED PATIENTS. (June 2017) - Le Bourgeois, A.; Labopin, M.; Blaise, D.; Ceballos, P.; Vigouroux, S.; Peffault De Latour, R.; Suarez, F.; Bulabois, C.; Bay, J.; Chantepie, S.; Deconinck, E.; Daguindau, E.; et al.